Lipo-dox and Cyclophosphamide /5-Fluorouracil in Patients With Metastatic Breast Cancer

TTY Biopharm

Status and phase: Unknown; Phase 2

Conditions: Metastatic Breast Cancer

Treatments: Drug: Lipo-Dox

Study type: Interventional

Funder types: Industry

Identifiers

NCT01451580

LD0411

Details and patient eligibility

About

To determine the overall objective response rate of pegylated liposomal doxorubicin （Lipo-Dox）combined with cyclophosphamide/5-FU as second-line treatment in patients with metastatic breast cancer.

Enrollment: 47 estimated patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically proved breast cancer with metastatic disease

Exclusion criteria

• life expectancy less than 3 months.